hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
With regard to extracting Bergamot oil from the fruit, the sfumatura or slow-folding process was the traditional technique for manually extracting the bergamot oil. In the 1840s the macchina calabrese (see image) was invented by Nicola Barillà. A few bergamots of similar size were placed between two metal cups. The lower cup was covered in spikes to hold the fruit still and the upper one was armed with sharp blades. The cups were rotated and the combination of pressure and movement of the upper cup caused oil and water to spray out of the fruit to be collected in a tin-lined copper bowl. The mixture of grated peel and oil would then be strained through woollen sacks. By more modern methods, the oil is extracted mechanically with machines called peelers, which scrape the outside of the fruit under running water to get an emulsion channeled into centrifuges for separating the essence from the water. The rinds of 100 bergamot oranges yield about 3 ounces (85 g) of bergamot oil.
Dysprosium perchlorate is an inorganic compound of dysprosium and the perchlorate ion, with the formula Dy(ClO4)3. It is known as an anhydrous salt and in hydrated forms, including the hexahydrate Dy(ClO4)3·6H2O. The anhydrous compound adopts the hexagonal structure characteristic of many rare-earth perchlorates.
The most recent model, the Dexcom G7, features a redesigned sensor and updated algorithm, yielding a MARD of 8.2% in adults and 8.1% in children. The newest iteration of the Dexcom CGM, the Dexcom G7 15-Day CGM, has an even lower MARD of 8% in adult users.
Sources: en.wikipedia.org
A dismissal will be "unfair" if it is "harsh, unjust or unreasonable", and according to the High Court in Byrne v Australian Airlines this includes the concept of the employer whose action "is disproportionate to the gravity of the misconduct" of the employee. Under section 387, the Fair Work Commission should consider factors including the employee's capacity and conduct, notice given, an opportunity to respond to any allegation, representation given, warnings before dismissal, and the enterprise's size and HR specialists. For example, in Pastrycooks Employees, Biscuit Makers Employees and Flour and Sugar Goods Workers Union (NSW) v Gartrell it was held too harsh to dismiss a bakery worker who refused to do a last minute delivery on his way home. In Agnew v Nationwide News Pty Ltd it was held to be unfair to fire employees who drank alcohol at lunchtime, because even though the company had a policy against this it was not consistently enforced especially among managers. In B, C and D v Australian Postal Corporation it was held to be unfair to dismiss three employees who accessed pornography at work because though there was a policy, it was not consistently enforced and there were no prior warnings to the three who were caught. According to the Fair Work Commission, it is relevant whether the employee has a past disciplinary history, whether an employer has a "history of toleration or condonation of the misconduct", and the employees' past conduct, length of service and consequences for dependents.
== Structure and contrast with other lipids == The 2,3-sn-glycerol structure and ether bond linkage are two key differences between lipids found in archaea vs those of bacteria and eukarya. The latter use 1,2-sn-glycerol, and mostly, ester bonds. Natural archaeol has 3R, 7R, 11R configurations for the three chiral centers in the isoprenoid chains. There are four structural variations, contributing to the complexity of the membrane lipids in function and properties. The two phytanyl chains can form a 36-member ring to yield macrocyclic archaeol. Hydroxylated archaeol has phytanyl chains hydroxylated at the first tertiary carbon atom, while sesterterpanyl archaeol have the phytanyl side chains with C25 sesterterpanyl chains, substituting at C2 of glycerol or at both carbons. Unsaturated archaeol, with the same carbon skeleton as standard archaeol but one or multiple double bonds in the phytanyl side chains is also discovered.
=== Prenatal tests === A prenatal test can be considered when the mother is a known or suspected carrier. Before invasive testing, determination of the fetal sex is important; while males are sometimes affected by this X-linked disease, female Duchenne muscular dystrophy is extremely rare. This can be achieved by ultrasound scan at 16 weeks or more recently by free fetal DNA (cffDNA) testing. Chorion villus sampling (CVS) can be done at 11–14 weeks and has a 1% risk of miscarriage. Amniocentesis can be done after 15 weeks and has a 0.5% risk of miscarriage. Non invasive prenatal testing can be done around 10–12 weeks. Another option in the case of unclear genetic test results is fetal muscle biopsy.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.